Background and Objectives：Matrix metalloproteinase-9 (MMP-9) plays an important role in the genesis of atherosclerotic plaque rupture and acute coronary syndrome (ACS), including an acute myocardial infarction (AMI). A single nucleotide polymorphism (SNP) in the MMP-9 promoter (-1562C>T) has recently been identified. This study investigated whether the SNP of the MMP-9 promoter is a significant risk factor for an AMI due to plaque rupture and if SNPs affect the transcription of the gene that elevates the MMP-9 expression level. Subjects and Methods：A polymerase chain reaction, followed by a restriction fragment length polymorphism analysis, was performed in 173 control participants and 206 AMI patients. The serum levels of MMP-9 in the groups with or without the SNP were measured, using ELISA, and compared. Results：There was a significantly higher incidence of the -1562C>T MMP-9 polymorphism in the AMI compared to the control group (27.6% vs. 17.9%, p=0.04). A multiple logistic regression analysis of the risk factors for coronary artery disease and the MMP-9 polymorphism showed the MMP-9 polymorphism to be an important factor in the prediction of an AMI (odds ratio 1.67, 95% confidence interval 1.02-2.67, p=0.04). Conclusion： The -1562C>T polymorphism in the MMP-9 promoter is a definite risk factor for an AMI, and is associated with elevated MMP-9 expression. These results suggest that a SNP in the MMP-9 promoter is strongly associated with an Acute Myocardial Infarction.
Introduction
The rupture of an atherosclerotic plaque is a major event in the pathogenesis of an acute myocardial infarction(AMI).
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Plaques that are vulnerable to rupture tend to have a large lipid-rich atheromatous core, a thin fibrous cap covering the core, active inflammatory cellular infiltration, particularly in the plaque shoulders effected by strong shear stress, and a reduced smooth muscle cell density collagen content in the fibrous cap. [3] [4] [5] [6] Matrix metalloproteinases(MMPs), mainly produced by infiltrating inflammatory cells, degrade the extracellular matrix, thereby contributing to the weakening of the cap and its subsequent rupture. 7) Of the many MMPs, MMP-9(gelatinase B) might play an important role in matrix degradation and the subsequent rupture of the atherosclerotic plaques, owing to its broad substrate specificity and distal position in the matrix proteolytic cascade. 8) MMP-9 is involved in the degradation of a broad spectrum of substrates, including collagen types IV, V, VII and X as well as gelatin, 9)10) and also degrades the proteoglycans and elastins, which are resistant to degradation by other MMPs, such as stromelysin and interstitial collagenase. 
Genotyping of the MMP-9 gene
The genomic DNA was extracted from the mononuclear cells of each participant, and the specific genotypes of the MMP-9 promoter identified using a polymerase chain reac- 
Assays of serum MMP-9
The peripheral blood was drawn from all AMI patients within 24hrs of admission, and stored at -80C. A standard sandwich enzyme immunoassay was performed to measure the serum MMP-9 concentrations, using commercially available kits with a monoclonal antibody against MMP-9 according to the manufacturer's instructions(R & D systems, MN, USA), but only on those patients with an AMI to determine the serum MMP-9 levels, according to the genotypes, at the time of plaque rupture. 
Statistical analysis
All statistical analyses were conducted between the control group and patients with AMI using the PC-SAS system (SAS Institute Inc., Cary, North Carolina, USA). The statistical differences in the frequency of each genotype between the groups were examined using a univariate analysis. The serum levels of MMP-9 in the AMI patients, both with and without the SNP in the MMP-9 promoter(that is, TT+CT)
were compared. All the continuous variables were analyzed using paired t-tests and all the categorical variables using χ 
Results
Characteristics of the study participants Table 1 shows the characteristics of the AMI patients and control subjects. Among the coronary artery risk factors, age and LDL cholesterol level were the only statistically different factors between the AMI patients and control subjects.
MMP-9 1562C>T polymorphism and AMI
The genotype frequency of the -1562C>T polymorphism in the 206 AMI patients and 173 controls was compared ( Table 2 Association between the MMP-9 polymorphisms and the serum level of MMP-9 in AMI patients Figure 2 shows a higher plasma MMP-9 level in the group with the -1562C>T polymorphism in the MMP-9 promoter (494.8 ng/mL) than in the group without(309.5 ng/mL, p=0.04).
A multiple logistic regression analysis, with the known coronary artery disease risk factors and MMP-9 polymorphism, was performed. In order to determine the predictive risk factors for an AMI, a multiple logistic regression analysis, with the forward stepwise selection, using all the clinical risk factors and the MMP-9 genotypes, was performed. The most predictive risk factor for an AMI was age(odds ratio 1.80, 95% confidence interval 1.20-2.72, p=0.004), followed by the SNP in the MMP-9 promoter(odds ratio 1.67, 95% confidence interval 1.02-2.67, p=0.04)( Table 3) .
Discussion
This study showed that the -1562C>T polymorphism in the promoter region of the MMP-9 gene has a significant and independent role in the development of an acute myocardial infarction in association with increased serum MMP-9 levels in the Korean population. We found that the T allele in the MMP-9 promoter was significantly more frequent in AMI patients than in control subjects, suggesting that patients with Recently, Zhang et al 12) reported a novel polymorphism (-1562C>T) in the promoter region of the MMP-9. The promoter region contains the 9-bp sequence(GCGCAC/TG-CC), an important regulatory element of gene expression, which appears to be a binding site for a transcription repressor pro-tein. The DNA-protein interaction is lost due to a C to T substitution at the polymorphism site, resulting in a Tallelic promoter, with higher promoter activity, and an increased level of MMP-9 synthesis. An autopsy study of the coronary arteries showed that subjects carrying this T allele had larger complicated lesion areas than those with the CC genotype, 14) suggesting the MMP-9 -1562C>T polymorphism contributes to the development of a plaque rupture by influencing the endogenous MMP-9 production. Indeed, in this study the serum level of MMP-9 was higher in the AMI patients with the MMP-9 polymorphism than in those without.
In contrast with our results, Wang et al 22) failed to show any relationship between a MMP-9 polymorphism and acute coronary syndrome in Caucasians. This discrepancy might have arisen from differences between the patients included in the two studies. Their study included patients with a myocardial infarction as well as those with unstable angina, which is a heterogeneous disorder from angina due to plaque rupture to that with a secondary precipitating cause. This might lead to an inappropriate selection of patients. Whereas, our study tried to include only those patients with AMI due to a plaque rupture. Furthermore, Wang's study included those with atypical chest pain as the control group, which leads to the inclusion of those with other inflammatory conditions. It can also be explained with respect to the population specificity, which suggests that a certain genetic variant may be relevant to a defined population only.
In conclusion, this study showed that a functional polymorphism in the promoter region of the MMP-9 gene is strongly associated with an Acute Myocardial Infarction in the Korean population, which was independent of known coronary risk factors. Further study on a larger population will be required to confirm this polymorphism as a potential novel genetic marker for a plaque rupture in Koreans. 
